Cargando…

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients

BACKGROUND: Malignant pleural mesothelioma is a rare tumour with increasing frequency throughout the world. Due to long latency after exposure to asbestos, restrictions in the production and use of asbestos have not yet alleviated the burden of mesothelioma. During the last decade, several trials co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovac, Viljem, Zwitter, Matjaz, Zagar, Tina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472938/ https://www.ncbi.nlm.nih.gov/pubmed/23077450 http://dx.doi.org/10.2478/v10019-012-0032-0

Ejemplares similares

Glioblastoma patients in Slovenia from 1997 to 2008
por: Smrdel, Uros, et al.
Publicado: (2014)

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2017)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
por: Strbac, Danijela, et al.
Publicado: (2018)

Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
por: Vivoda Tomšič, Martina, et al.
Publicado: (2022)

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
por: Zwitter, Matjaz, et al.
Publicado: (2014)

Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma
por: Goričar, Katja, et al.
Publicado: (2015)

Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
por: Zwitter, Matjaz, et al.
Publicado: (2011)

The Influence of Genetic Variability in IL1B and MIR146A on the Risk of Pleural Plaques and Malignant Mesothelioma
por: Piber, Petra, et al.
Publicado: (2020)

Trends in Population-based Cancer Survival in Slovenia
por: Zadnik, Vesna, et al.
Publicado: (2021)

Factors Affecting Attitudes towards COVID-19 Vaccination: An Online Survey in Slovenia
por: Petravić, Luka, et al.
Publicado: (2021)

Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria
por: Vivoda Tomšič, Martina, et al.
Publicado: (2019)

Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial
por: Vrankar, Martina, et al.
Publicado: (2014)

Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
por: Goričar, Katja, et al.
Publicado: (2017)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients
por: Goričar, Katja, et al.
Publicado: (2021)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Chemotherapy for malignant pleural mesothelioma: past results and recent developments
por: Tomek, S, et al.
Publicado: (2003)

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2019)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
por: Kovac, Viljem, et al.
Publicado: (2015)

Serum Calretinin as a Biomarker in Malignant Mesothelioma
por: Zupanc, Cita, et al.
Publicado: (2021)

The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2018)

The Influence of Genetic Variability of DNA Repair Mechanisms on the Risk of Malignant Mesothelioma
por: Levpuscek, Kristina, et al.
Publicado: (2019)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor
por: Smrdel, Uros, et al.
Publicado: (2016)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Survival Effect of Complete Multimodal Therapy in Malignant Pleural Mesothelioma
por: Sayan, Muhammet, et al.
Publicado: (2022)

Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma
por: Karatkevich, Darya, et al.
Publicado: (2022)

Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Genetic Polymorphisms in Aquaporin 1 as Risk Factors for Malignant Mesothelioma and Biomarkers of Response to Cisplatin Treatment
por: Senk, Barbara, et al.
Publicado: (2019)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9j9qrsqf4t1pk2d5ghdqdqle8g